erythropoiesis-stimulating agents

erythropoiesis-stimulating agents

Drugs, such as epoetin alpha and darbepoetin alpha used to stimulate red cell production in anaemia. In the case of anaemia caused by anti-cancer chemotherapy, research in the late 1990s and subsequently has suggested that the risks associated with such treatment include thromboembolic disease and promotion of tumour growth. There are indications that erythropoietin receptors occur on cancer cells.
References in periodicals archive ?
In addition, the company has initiated the Phase 2 FO2RWARD study of vadadustat in dialysis-dependent chronic kidney disease patients who are hyporesponsive to erythropoiesis-stimulating agents, and expects to commence the Phase 3 TRILO2GY study to further evaluate a three-times-weekly dosing regimen for vadadustat.
Importantly, during the study, patients were not allowed to receive any intravenous (IV) or oral iron, or erythropoiesis-stimulating agents (ESAs).
When the endogenous production of erythropoietin is disrupted because of illness or medications, normal red blood cell levels are maintained by an injecting erythropoiesis-stimulating agents (ESAs).
Red blood cell-boosting drugs called erythropoiesis-stimulating agents (ESAs) are used to fight anaemia, but these medications increase the risk of blood clots, and the U.
The development of erythropoiesis-stimulating agents (ESAs) in the 1980s revolutionized anemia management; it provided patients and clinicians with a much-needed treatment option and hope for improved quality of life.
Medicare spends more than $2 billion every year for erythropoiesis-stimulating agents (ESAs).
Medical Center, provide 29 chapters by oncologists, geriatricians, psychiatrists, and palliative care and other specialists from the US, Europe, and Australia who discuss assessment, management of specific solid tumors and hematologic malignancies, the impact of age on the pharmacology of cancer therapy, surgical and radiation oncology in the older adult, myeloid growth factors, erythropoiesis-stimulating agents, quality of life, optimizing functional status, and managing depression, pain, fatigue, and other symptoms.
The FDA issued more conservative dosing guidelines for the use of erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients who face increased risks of cardiovascular events associated with these drugs.
FDA is recommending new, more conservative dosing recommendations for erythropoiesis-stimulating agents [ESAs] for patients with chronic kidney disease," Dr.
Academic studies have shown that more frequent maintenance doses of iron improve therapeutic response to erythropoiesis-stimulating agents (ESA's), thereby decreasing the ESA doses needed to maintain hemoglobin in the target range.
Erythropoiesis-stimulating agents are contraindicated for a hemoglobin of greater than 10 and carry significant risk.

Full browser ?